Atezolizumab Dosage

Medically reviewed on May 5, 2017.

Usual Adult Dose for Non-Small Cell Lung Cancer

1200 mg IV over 60 minutes every 3 weeks until disease progression or unacceptable toxicity

Comments:
-If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes.
-Do not administer this drug as an IV push or bolus.

Use: For the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
-Have disease progression during or following platinum-containing chemotherapy -Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy

Uses:
-For the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
1) Are not eligible for cisplatin-containing chemotherapy
2) Have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant chemotherapy
-For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving this drug

Usual Adult Dose for Urothelial Carcinoma

1200 mg IV over 60 minutes every 3 weeks until disease progression or unacceptable toxicity

Comments:
-If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes.
-Do not administer this drug as an IV push or bolus.

Use: For the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
-Have disease progression during or following platinum-containing chemotherapy -Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy

Uses:
-For the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
1) Are not eligible for cisplatin-containing chemotherapy
2) Have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant chemotherapy
-For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving this drug

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

Mild hepatic impairment: No adjustment recommended
Moderate to severe hepatic impairment: Data not available

Dose Adjustments

Dose Modifications:
No dose reductions of this drug are recommended.

Withhold therapy for any of the following:
-Grade 2 pneumonitis
-Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 3 and up to 5 times upper limit of normal (ULN) or total bilirubin greater than 1.5 and up to 3 x ULN
-Grade 2 or 3 diarrhea or colitis
-Symptomatic hypophysitis, adrenal insufficiency, hypothyroidism, hyperthyroidism, or Grade 3 or 4 hyperglycemia
-Grade 2 ocular inflammatory toxicity
-Grade 2 or 3 pancreatitis, or Grade 3 or 4 increases in amylase or lipase levels (greater than 2 x ULN)
-Grade 3 or 4 infection
-Grade 2 infusion-related reactions
-Grade 3 rash

Therapy may be resumed in patients whose adverse reactions recover to Grade 0 or 1.

Permanently discontinue therapy for any of the following:
-Grade 3 or 4 pneumonitis
-AST or ALT greater than 5 x ULN or total bilirubin greater than 3 x ULN
-Grade 4 diarrhea or colitis
-Grade 4 hypophysitis
-Myasthenic syndrome/myasthenia gravis, Guillain-Barré or meningoencephalitis (all grades)
-Grade 3 or 4 ocular inflammatory toxicity
-Grade 4 or any grade of recurrent pancreatitis
-Grade 3 or 4 infusion-related reactions
-Grade 4 rash

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Administer the initial infusion over 60 minutes through an IV line with or without a sterile, non-pyrogenic, low-protein binding in-line filter (pore size of 0.2 to 0.22 micron).
-If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes.
-Do not coadminister other drugs through the same intravenous line.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer